** Shares of India's Granules GRAN.NS jump 1.30% to 713.70 rupees
** Drugmaker's Q4 profit jumps 32.6% y/y to 2.02 billion rupees ($21.30 million), on strong demand for key products across major markets
** Total revenue from operations rises 21.7% y/y
** Europe's revenue share rose to 17% in Q4 FY26 from 8% in Q4 FY25
** Emkay said regulatory clearance of the Gagillapur facility in FY27 could boost formulation sales; introduces FY29 estimates and expects ~26% PAT CAGR over FY26–FY29
** GRAN rated "buy" on average by seven analysts, median PT: 685 rupees - data compiled by LSEG
** YTD, stock up ~18.6%
($1 = 94.8400 Indian rupees)
(Reporting by Bipasha Dey in Bengaluru)
((Bipasha.Dey@thomsonreuters.com;))